These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24432379)

  • 21. Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.
    Kaneko N; Kita A; Yamanaka K; Mori M
    Leuk Res; 2013 Sep; 37(9):1156-61. PubMed ID: 23746965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.
    Chen J; Pise-Masison CA; Shih JH; Morris JC; Janik JE; Conlon KC; Keating A; Waldmann TA
    Blood; 2013 Mar; 121(11):2029-37. PubMed ID: 23321252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
    Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
    Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
    Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
    Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.
    Kita A; Mitsuoka K; Kaneko N; Nakata M; Yamanaka K; Jitsuoka M; Miyoshi S; Noda A; Mori M; Nakahara T; Sasamata M
    J Pharmacol Exp Ther; 2012 Oct; 343(1):178-83. PubMed ID: 22787117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus.
    Carew JS; Espitia CM; Zhao W; Mita MM; Mita AC; Nawrocki ST
    Mol Cancer Ther; 2015 Jun; 14(6):1404-13. PubMed ID: 25808836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
    Sim MY; Huynh H; Go ML; Yuen JSP
    PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.
    Cheng XJ; Lin JC; Ding YF; Zhu L; Ye J; Tu SP
    Oncotarget; 2016 Feb; 7(6):7096-109. PubMed ID: 26771139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
    Gholizadeh S; Dolman EM; Wieriks R; Sparidans RW; Hennink WE; Kok RJ
    Pharm Res; 2018 Mar; 35(4):85. PubMed ID: 29516187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells.
    Cheng SM; Chang YC; Liu CY; Lee JY; Chan HH; Kuo CW; Lin KY; Tsai SL; Chen SH; Li CF; Leung E; Kanwar JR; Huang CC; Chang JY; Cheung CH
    Br J Pharmacol; 2015 Jan; 172(1):214-34. PubMed ID: 25220225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
    Huang YT; Cheng CC; Lin TC; Chiu TH; Lai PC
    Oncol Rep; 2014 Feb; 31(2):771-80. PubMed ID: 24297644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
    Smith AM; Little EB; Zivanovic A; Hong P; Liu AK; Burow R; Stinson C; Hallahan AR; Moore AS
    Leuk Res; 2015 Apr; 39(4):435-44. PubMed ID: 25659731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair.
    Qin Q; Cheng H; Lu J; Zhan L; Zheng J; Cai J; Yang X; Xu L; Zhu H; Zhang C; Liu J; Ma J; Zhang X; Dai S; Sun X
    J Hematol Oncol; 2014 Aug; 7():62. PubMed ID: 25139395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.
    Tao YF; Lu J; Du XJ; Sun LC; Zhao X; Peng L; Cao L; Xiao PF; Pang L; Wu D; Wang N; Feng X; Li YH; Ni J; Wang J; Pan J
    BMC Cancer; 2012 Dec; 12():619. PubMed ID: 23267699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
    Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
    Kita A; Nakahara T; Yamanaka K; Nakano K; Nakata M; Mori M; Kaneko N; Koutoku H; Izumisawa N; Sasamata M
    Leuk Res; 2011 Jun; 35(6):787-92. PubMed ID: 21237508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. YM155 induces EGFR suppression in pancreatic cancer cells.
    Na YS; Yang SJ; Kim SM; Jung KA; Moon JH; Shin JS; Yoon DH; Hong YS; Ryu MH; Lee JL; Lee JS; Kim TW
    PLoS One; 2012; 7(6):e38625. PubMed ID: 22723871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.
    Koike H; Nitta T; Sekine Y; Arai S; Furuya Y; Nomura M; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1705-13. PubMed ID: 24916171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression.
    Mir R; Stanzani E; Martinez-Soler F; Villanueva A; Vidal A; Condom E; Ponce J; Gil J; Tortosa A; Giménez-Bonafé P
    Gynecol Oncol; 2014 Jan; 132(1):211-20. PubMed ID: 24262875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.